论文部分内容阅读
目的运用药物经济学的方法评价急性心肌梗死(AMI)溶栓治疗的最佳方案。方法对AMI患者的溶栓治疗费用-效果进行分析。结果尿激酶、链激酶和阿替普酶治疗AMI的效果基本相同(P>0.05),治疗费用相差却十分悬殊,以阿替普酶治疗费用最高,链激酶次之,尿激酶最低。结论对于AMI溶栓治疗,尿激酶的费用-效果比(C/E)最好,链激酶次之,阿替普酶最差。
Objective To evaluate the best strategy of thrombolytic therapy for acute myocardial infarction (AMI) by the method of pharmacoeconomics. Methods The costs-effectiveness of thrombolysis in patients with AMI was analyzed. Results The effects of urokinase, streptokinase and alteplase on AMI were basically the same (P> 0.05). However, the difference of treatment cost was very poor. The treatment cost was the highest with alteplase, followed by streptokinase and lowest with urokinase. Conclusions The cost-effect ratio (C / E) of urokinase is the best for AMI thrombolytic therapy, followed by streptokinase and alteplase is the worst.